MMP2 Protein

Catalog No. ABIN7318047

This Recombinant MMP2 protein is expressed in HEK-293 Cells.

Quick Overview for MMP2 Protein (ABIN7318047)

Target: MMP2 (Matrix Metalloproteinase 2 (MMP2))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: HEK-293 Cells

Purity: > (74.7+17.3) % as determined by reducing SDS-PAGE.

Product Details

Purpose: Recombinant Human MMP-2 Protein (Active)

Sequence: Met 1-Cys 660

Characteristics: A DNA sequence encoding the native human MMP2 (NP_004521.1) (Met 1-Cys 660) was expressed and purified.

Endotoxin Level: < 1.0 EU per μg of the protein as determined by the LAL method.

Biological Activity Comment: Measured by its ability to cleave the fluorogenic peptide substrate Mca-PLGL-Dpa-AR-NH2 (AnaSpec, Catalog # 27076). The specific activity is > 1,000 pmoles/min/μg.2. Measured by its binding ability in a functional ELISA.3. Immobilized human MMP2 at 10 μg/mL (100 μl/well) can bind human TIMP2/Fc. The EC50 of human TIMP2/Fc is 0.02 μg/mL.(Activation description: The proenzyme needs to be activated by APMA for an activated form)

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Please refer to the printed manual for detailed information.

Buffer: Lyophilized from sterile PBS, pH 7.4

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Target Details

Target: MMP2 (Matrix Metalloproteinase 2 (MMP2))

Alternative Name: MMP-2

Background:

Background: Matrix Metalloproteinase-2 (MMP-2) is an enzyme that degrades components of the extracellular matrix and thus plays a pivotal role in cell migration during physiological and pathological processes. MMP-2 expression is dependent on extracellular matrix metalloproteinase inducer (EMMPRIN), Her2/neu, growth factors, cytokines, and hormones. Pro-MMP-2 activation needs MT1-MMP and TIMP-2 contribution. MMP-2 is changed in distribution and increased in amount in the ventral cochlear nucleus after unilateral cochlear ablation. A low level of MMP-2 is linked to favorable prognosis in patients with a hormone receptor-negative tumor, usually associated with high risk. As a zymogen requiring proteolytic activation for catalytic activity, MMP-2 has been implicated broadly in the invasion and metastasis of many cancer model systems, including human breast cancer (HBC). Blocking MMP-2 secretion and activation during breast carcinoma development may decrease metastasis. The detection of active MMP-2 alone or the rate of pro-MMP-2 and active MMP-2 is considered a very sensitive indicator of cancer metastasis. Modulation of MMP-2 expression and activation through specific inhibitors and activators may thus provide a new mechanism for breast cancer treatment.

Synonym: 72 kDa Type IV Collagenase, 72 kDa Gelatinase, Gelatinase A, Matrix Metalloproteinase-2, MMP-2, TBE-1, MMP2, CLG4A,CLG4,MMP-II,MONA,TBE-1

NCBI Accession: NP_004521

Pathways: Activation of Innate immune Response